US2019142766A1PendingUtilityA1
Use of rasagiline for the treatment of restless legs syndrome
Est. expiryApr 3, 2026(expired)· nominal 20-yr term from priority
A61P 43/00A61P 25/00A61P 25/08A61P 25/14A61P 21/00A61K 31/428A61K 31/16A61K 31/135A61K 2300/00
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A pharmaceutical composition comprising in unit dosage form R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof and at least one of pergolide, pramipexole, oxycodone, clonazepam, carbamazepine, gabapentin, valproate, ropinirole or clonidin.Join the waitlist — get patent alerts
Track US2019142766A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.